Female Reproductive System Adenocarcinoma

Female Reproductive System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

454 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 158
Recruiting: 74
Ph III recruiting: 10
Growth YoY: +19%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (59)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06393751	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer	withdrawn	Phase 1 / Phase 2	0	National Cancer Institute (NCI)NIH	0	Jun 3, 2025	clinicaltrials
NCT02756130	Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)	withdrawn	Phase 1 / Phase 2	0	Jonsson Comprehensive Cancer CenterOTHER	1